Sirnaomics

Sirnaomics OCF Margin

The Operating Cash Flow Margin of Sirnaomics (2257.HK) as of Oct 28, 2026 is -1,109.56 %. In the previous year, Operating Cash Flow Margin was -138,747.31 % — a change of -99.20% (higher).

OCF Margin

-1,109.56 %

YoY

-99.20%

Last updated:

Operating Cash Flow Margin of Sirnaomics is 2024 -1,109.56 % . Operating Cash Flow Margin of Sirnaomics was 2023 -138,747.31 % . It decreases by -99.20% higher compared to the previous year.

The Sirnaomics OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2019
-16,367.04 USD
Jan 1, 2021
-80,243.66 USD
Jan 1, 2022
-12,582.70 USD
Jan 1, 2023
-138,747.31 USD
Jan 1, 2024
-1,109.56 USD
The Sirnaomics OCF Margin history
YEAROCF MarginYoY
-1,109.56 %-99.20%
-138,747.31 %+1,002.68%
-12,582.70 %-84.32%
-80,243.66 %+390.28%
-16,367.04 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sirnaomics Stock analysis

What does Sirnaomics do? Sirnaomics Ltd. develops RNAi-based therapeutics through its clinical-stage biotechnology subsidiaries, focusing on unmet medical needs. The company's lead products STP705 and STP707 target multiple indications, with STP705 addressing nonmelanoma skin cancer, recurrent keloids, hypertrophic scars, and solid liver tumors, while STP707 targets solid tumors including liver cancer and metastatic cutaneous squamous-cell skin cancer. The firm leverages dual delivery platforms Polypeptide nanoparticle (PNP) and GalAhead to advance its drug candidates. Its primary customers are healthcare providers and patients requiring treatments for these specific conditions. Sirnaomics Ltd. generates revenue through the development and potential future commercialization of its RNAi therapeutics. The company's business model centers on clinical-stage drug development, with STP705 and STP707 representing key assets in its pipeline. The firm's focus on therapeutic areas with significant unmet medical needs positions it to secure partnerships and future licensing agreements with pharmaceutical companies seeking innovative treatments. The target segments include patients with nonmelanoma skin cancer, solid tumors, and other conditions covered by its lead drug candidates. The company's dual delivery platforms Polypeptide nanoparticle (PNP) and GalAhead enable targeted drug delivery for its therapeutic applications. These platforms are integral to the development of STP705 and STP707, supporting their use in treating various cancers and skin conditions. Sirnaomics Ltd. monetizes its technology by advancing its pipeline toward clinical trials and eventual commercialization, with potential revenue streams from partnerships, licensing, and future product sales once approved. Sirnaomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sirnaomics stock

Operating Cash Flow Margin of Sirnaomics is -1,109.56 % in 2024.

Operating Cash Flow Margin of Sirnaomics changed from -138,747.31 % to -1,109.56 %, representing a -99.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Sirnaomics since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Sirnaomics with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Sirnaomics

All Key Metrics — Sirnaomics